Features | VJOncology

177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC

As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

PHS290: a novel scoring algorithm provides a promising approach to screening for prostate cancer in diverse populations

A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…

Highlights from ASCO GI 2022

VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium!

Top picks from SABCS 2021

The San Antonio Breast Cancer Symposium (SABCS) took place on the 7-10 December 2021, both virtually and in-person. We heard…

FDA grants priority review for fixed-dose relatlimab plus nivolumab in melanoma based on RELATIVITY-047

The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting…

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung…